Advanced Solutions Life Sciences

What Advanced Solutions Life Sciences does

Advanced Solutions Life Sciences (ASLS) is a privately held LLC that develops automated 3D bioprinting systems and software for life science laboratories, pharmaceutical researchers, and healthcare providers performing reconstructive procedures. The company's flagship platform is the BioAssemblyBot (BAB) — a patented, UL- and cGMP-certified intelligent robotic system offered in BAB200, BAB400, and BAB500 configurations — which adapts more than 60 years of industrial robotic innovation to fabricate biological structures including tissues, organs, organoids, and vascularized microvessels. The hardware is paired with BABIntelligence, a proprietary software layer that automates process control and optimization, and is sold alongside specialized bundles such as Organoid360 (organoid research), PrecisionOne (precision bioprinting), and a Microvessels vascularization technology.

ASLS generates revenue from three streams: capital equipment sales of BAB systems, software subscriptions and licenses for BABIntelligence and related workflow software, and one-time bundle product sales. Pricing is quote-based via "Request a Quote" and "Contact Us" channels, with multi-year contracts typical of enterprise capital equipment. The company serves three customer segments: life science laboratories and research institutions (primary), healthcare providers such as VA Hospital Seattle for reconstructive surgery applications, and pharmaceutical companies using bioprinted organoids for drug testing. ASLS operates from its Louisville, KY headquarters and a Manchester, NH research laboratory, and is publicly endorsed by ARMI Executive Director Dean Kamen as "the poster child company for the ARMI ecosystem," with the BioAssembly Platform winning NH Tech Alliance Product of the Year 2025.

Name

Advanced Solutions Life Sciences

Legal name

Advanced Solutions Life Sciences, LLC

Website

https://lifesciences.solutions

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Advanced Solutions Life Sciences develops patented BioAssemblyBot robotic 3D bioprinters and BABIntelligence software for life science laboratories, pharmaceutical drug-testing researchers, and reconstructive healthcare providers to fabricate tissues, organs, organoids, and vascularized constructs.

Ownership category

akta.pro rank

Product category

3D Bioprinting Systems

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

3D Bioprinting & Biofabrication (HLAAAGAC)

akta.pro secondary industries

Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG), Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), Medical & Dental Prototyping (Models, Guides, Pre-Op Planning) (IMAAAFAI)

Keywords

• 3D bioprinting systems
• Tissue engineering platforms
• Regenerative medicine robotics
• Organoid biofabrication
• Vascularization technology

Headquarters

HQ city

Louisville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. BioAssemblyBot Hardware Sales: ASLS sells its proprietary BioAssemblyBot robotic platforms (BAB200, BAB400, BAB500) which are UL and cGMP certified 3D bioprinting systems. These are major capital equipment purchases for life science laboratories and research institutions.
2. Software Licenses and Subscriptions: The company generates revenue from BABIntelligence software and other software solutions that support the BioAssemblyBot platforms, likely through licensing or subscription models.
3. Bundle Products (Organoid360, PrecisionOne): ASLS offers integrated bundles combining hardware and software solutions for specific applications like organoid production and precision bioprinting, sold as complete packages.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Advanced Solutions Life Sciences designs, manufactures, and sells the patented BioAssemblyBot (BAB), an intelligent, UL- and cGMP-certified robotic 3D bioprinting platform used by life science laboratories to build and assemble biological structures such as tissues, organs, organoids, and microvessels. Its BABIntelligence software, application-specific bundles (Organoid360, PrecisionOne), and Microvessels vascularization technology form an integrated offering for regenerative medicine, drug testing, and reconstructive surgery research.

Product overview

Advanced Solutions Life Sciences offers an integrated portfolio of bioprinting products and software centered around the BioAssemblyBot platform. The core offering is the award-winning BioAssemblyBot (BAB), a patented UL and cGMP certified robotic system for building biological structures. This platform is enhanced by the proprietary BABIntelligence software for intelligent automation. The product lineup includes specialized bundles such as Organoid360 and PrecisionOne for specific research applications, standalone Software offerings for 3D tissue model development, and Microvessels technology for vascularization. The company positions these as integrated solutions designed to streamline research, improve workflows, and accelerate results for modern life science laboratories.

Differentiator

Problem solved

Functional benefit

Brands

• BioAssemblyBot: The patented, UL and cGMP certified, award-winning BioAssemblyBot platform is an intelligent agile robotic system used to build and assemble biological structures. Also referred to as BAB.
• Organoid360 Bundle
• PrecisionOne
• BABIntelligence

Products and services

• BioAssemblyBot (BAB) — BAB200, BAB400, BAB500

Quantifiable outcome

• Living bone fabricated to match both patient anatomy and biology, enabling functions like eating and speaking for reconstructive surgery patients

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Four partnerships are on record, tiered core, minor and moderate.

• ARMI (Advanced Regenerative Manufacturing Institute)coreStrategic or Co-development PartnerASLS is described as 'the poster child company for the ARMI ecosystem' by Dean Kamen, Executive Director of ARMI. The BioAssemblyBot and Angiomics biofabrication platforms are described as valuable contributions toward ARMI's mission to mass produce human organs. ASLS is recognized as an entrepreneurial, talented team and leading members for ARMI.
• VA Hospital SeattlecoreStrategic or Co-development PartnerASLS's reconstructive surgery technology originated approximately 5½ years ago at a VA hospital in Seattle. The technology was developed to help a veteran who lost part of his jaw during tumor removal surgery by building living bone that matches both the patient's anatomy and biology, enabling functions like eating and speaking. This partnership represents the foundational application for ASLS's bone fabrication technology.
• NH Tech AllianceminorOthersNH Tech Alliance recognized ASLS with the Product of the Year 2025 award for the BioAssembly Platform with BABIntelligence, providing industry recognition and visibility.
• Dean KamenmoderateStrategic or Co-development PartnerDean Kamen, Executive Director of ARMI, has publicly endorsed ASLS's technology, stating that BioAssemblyBot and Angiomics biofabrication platforms are valuable inventions and contributions toward ARMI's mission to mass produce human organs. His endorsement provides significant credibility and visibility for ASLS.

Scale indicators3 records

Expansion highlights5 records

Direct peers

• CELLINK (BICO): CELLINK, part of BICO, is one of the most established bioprinting hardware and consumables companies globally. It competes directly with ASLS's BioAssemblyBot in 3D bioprinters, bioinks, and lab automation for tissue engineering, with broader product depth and significantly larger scale.
• Organovo: Organovo is a pioneering 3D bioprinting company developing functional human tissues for drug discovery and therapeutic applications. It is a direct peer in the 3D bioprinting and tissue engineering space, though focused more on tissue therapeutics than hardware sales.
• Aspect Biosystems: Aspect Biosystems develops microfluidic 3D bioprinting platforms for tissue engineering and regenerative medicine. It competes with ASLS in bioprinting hardware targeting drug discovery and therapeutic tissue fabrication, with a focus on pancreas and other tissues.
• regenHU: regenHU is a Swiss-based manufacturer of 3D bioprinters and bioinks for tissue engineering and regenerative medicine research. It directly competes with ASLS's BioAssemblyBot in multi-axis bioprinting hardware for research and translational applications.
• Poietis: Poietis is a French bioprinting company offering laser-assisted 3D bioprinting platforms and bioinks for tissue engineering. It directly overlaps with ASLS in bioprinting hardware technology targeting regenerative medicine and pharmaceutical research.

Broad incumbents

• 3D Systems: 3D Systems is a major 3D printing incumbent that has expanded into bioprinting (e.g., acquisition of Allevi, regenerative medicine initiatives). It is a broad incumbent with overlapping bioprinting capabilities but operates across a much wider industrial and healthcare portfolio than ASLS.
• Stratasys: Stratasys is a global leader in polymer and industrial 3D printing that has explored bioprinting and life science applications. It is a broad incumbent with overlapping additive manufacturing capabilities for healthcare, though bioprinting is not its primary focus.

Emerging players

• Pandorum Technologies: Pandorum Technologies is an Indian biotech developing 3D bioprinted tissues including cornea and liver tissues for therapeutic use. It is an emerging player with partial overlap in bioprinting and tissue engineering, though more focused on therapeutic tissue development than hardware platforms.
• Prellis Biologics: Prellis Biologics uses holographic 3D bioprinting to build vascularized human tissues and organoids for drug discovery and transplantation. It is an emerging player with overlapping technology (bioprinting, vascularization, organoids) but differentiated printing modality and stronger drug discovery focus.

Regional players

• Rokit Healthcare: Rokit Healthcare is a Korean regenerative medicine and bioprinting company focused on skin, cartilage, and bone tissue fabrication using its proprietary 3D bioprinters. It is a regional player with comparable bioprinting and reconstructive tissue applications, primarily serving Asian markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCXg35GQIUJ5ZU89StOecFUA
• LinkedInlinkedin.com/company/advanced-solutions-life-sciences
• Xx.com/ASILifeScience

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advanced Solutions Life Sciences